The
Pharmabiotic Research Institute (PRI) is Europe’s leading organisation dedicated to microbiome regulatory science. Established in 2010 as a non-profit association, PRI works to
advance microbiome-based innovation by helping researchers, developers, regulators, and policymakers navigate the scientific and regulatory pathways required to bring microbiome products to market.
With
more than 70 members from industry and academia, PRI represents Europe’s largest microbiome regulatory science network, covering nearly every stage of the product development lifecycle. Through its collaborative “Share & Learn” model, PRI identifies regulatory gaps, develops scientific consensus, and fosters dialogue with competent authorities to support the safe, effective, and timely development of microbiome-based innovations.
By
advancing regulatory science, contributing to
standards and policy discussions, facilitating
pre-competitive collaboration, and helping regulators and policymakers understand the scientific and technical specificities of microbiome-based innovations, PRI works to clarify the scientific and regulatory requirements relevant to microbiome-based innovations. Through these activities, alongside its direct support and mentorship of members, PRI helps reduce regulatory uncertainty, de-risk innovation, and accelerate the translation of microbiome research into products and solutions that benefit health, food systems, and environmental sustainability.